| Nov 12 |
RAPT Therapeutics GAAP EPS of -$0.47 beats by $0.11
|
| Nov 12 |
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
|
| Nov 11 |
Crude Oil Down 3%; Aramark Posts Upbeat Earnings
|
| Nov 11 |
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull
|
| Nov 11 |
RAPT scraps zelnecirnon program, stock plunges 46% (update)
|
| Nov 11 |
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
|
| Nov 9 |
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky
|
| Sep 29 |
RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now
|
| Sep 25 |
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability
|
| Aug 8 |
RAPT Therapeutics GAAP EPS of -$0.71 beats by $0.05
|
